Prior biologic therapy:\r\n* Patients must have discontinued all biologic or investigational therapy at least 21 days before registration
Finasteride, bicalutamide and nilutamide discontinued at least 4 weeks prior to registration
Prior therapy: Patients must have discontinued all chemotherapy, investigational therapy or biologic therapy at least 14 days prior to initiating study treatment (with the exception of trastuzumab for patients with HER2+ breast cancer)
Prior use of hormone contraceptives and replacement therapy is allowed (e.g., estrogen and/or progestin), but must have been discontinued at least 30 days prior to the study enrollment; vaginal preparations (e.g., Vagifem or Estring) are allowed
Patients must have discontinued all biologic therapy at least 21 days before participation
Has been permanently discontinued from tazemetostat therapy due to adverse event, intolerance or treatment failure
Prior chemotherapy, other investigational agents, or radiation must be discontinued for at least 28 days prior to the first administration of COTI-2. Hormone treatments must be discontinued for at least 28 days prior to the first administration of COTI-2.
All previous cancer therapy (with the exception of hydroxyurea) including donor lymphocyte infusions must have been discontinued at least 2 weeks prior to treatment in this study
Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptable
Have discontinued all previous cancer therapies (except nonsteroidal aromatase inhibitors for participants in Part B2), and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half lives prior to study enrollment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days
Patients must have discontinued enzalutamide at least 28 days prior to enrollment.
Patients must have discontinued all biologic therapy at least 14 days prior to registration
Participants must have discontinued EGFR targeted therapy prior to the first dose of study drug.
Prior biologic therapy: Patients must have discontinued all biologic therapy at least 21 days before registration
Patients with a diagnosis of advanced CML must have been treated with 3 prior TKIs, and the last therapy must have been discontinued 14 days prior to starting OTS167.
Patients with a diagnosis of advanced CML must have been treated with 3 prior TKIs, and the last therapy must have been discontinued 14 days prior to starting OTS167.
Prior frontline therapy for B-CLL must have been discontinued >= 56 days but =< 365 days prior to registration; NOTE: Patients on supportive care therapy due to use of specific induction regimen such as antibiotics may continue on those treatments at the discretion of the treating physician
PHASE I: Any prior radiation therapy must be discontinued at least four weeks prior to enrollment
PHASE II: Any prior radiation therapy must be discontinued at least four weeks prior to enrollment
Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the exception of hydroxyurea and steroids) prior to starting therapy; for patients receiving ALL maintenance with 6-mercaptopurine, methotrexate, vincristine, and steroids - these agents should be discontinued at least 48 hours prior to start of study drugs; for patients on oral targeted therapies (such as imatinib, dasatinib, ponatinib), - these agents should be discontinued at least 48 hours prior to start of study drugs
Patients on antiplatelet/anticoagulant medication that cannot safely be discontinued 5-7 days prior to the procedure
Received any therapies intended to treat malignancy within 14 days of first receipt of DS-3032b (except for hydroxyurea, which must be discontinued at least 48 hours prior to study treatment).
Prior systemic treatment was discontinued for at least 2 weeks prior to the Baseline Visit.
Patients must have discontinued all previous systemic therapies and recovered from side effects due to systemic treatment for more than 14 days prior to starting on treatment
Patients must have discontinued all previous biologic therapies and recovered from side effects due to biologic treatment for more than 14 days prior to starting on treatment
Prior use of duvelisib if discontinued due to toxicity
For the romidepsin arm of the study, prior therapy with romidepsin if discontinued due to toxicity
Any prior therapy for B-CLL must have been discontinued >= 28-days prior to registration
Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment
Has been permanently discontinued from study treatment in the parent study for any reason.
Patients may have received prior therapy (including chemotherapy, biologic/targeted therapy and immunotherapy) for treatment of endometrial cancer; all therapy must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 30 days prior to registration
The subject must have discontinued any endocrine therapy for at least 2 weeks before the first dose of study treatment; in the cases of fulvestrant and leuprolide, these must be discontinued for at least 4 weeks before the first dose of study treatment
Any prior radiation therapy must be discontinued at least four weeks prior to registration
Discontinued all prior treatment for cancer at least 14 days prior to initial dose of study treatment.
Treatment with erlotinib must be discontinued at least 3 days prior to first dose of tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be discontinued at least 3 days prior to first dose of tesevatinib
Any prior radiation therapy must be discontinued at least four weeks prior to registration.
Bicalutamide (Casodex) and nilutamide discontinued < 6 weeks prior to registration
Prior therapy with romidepsin if discontinued due to toxicity
Other investigational drugs within 4 weeks prior to enrollment, unless cleared by the principal investigator; previous fixed-dose IL-2 therapy that was discontinued prior to 4 weeks is permitted
Any prior radiation therapy must be discontinued at least 4 weeks prior to study treatment initiation
Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptable
Prior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued >= 4 weeks prior to randomization
Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptable
Prior therapy with romidepsin if discontinued due to toxicity
Chemotherapy within 3 weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued 24 hours prior to starting study drug)
Prior Navelbine allowed provided Navelbine therapy discontinued >= 12 months from day 1 of treatment under this protocol
Any prior radiation therapy must be discontinued at least four weeks prior to registration
Patient may not have been resistant to any other prior TKI therapy; prior TKI therapy must only have been discontinued due to intolerance
Treatment with any of the following hormone replacement therapies, unless discontinued at least 14 days prior to the first dose of study treatment:
Discontinued all previous cancer therapies, and any agents that have not received regulatory approval, for at least 21 days and recovered from the acute effects of therapy. Must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.
All previous therapies must have been discontinued at least 4 weeks prior to initiation of the administration of this study’s drugs
Targeted therapy must have been discontinued =< 14 days prior to initiation of study therapy
Use of plaquenil must be discontinued two weeks prior to first study treatment
Treatment with chemotherapy or biologic therapy within 3 weeks, except for hydroxyurea, which must be discontinued prior to treatment on study
Receiving hormone replacement therapy that cannot be discontinued
Use of medications known to interfere with 123I-mIBG uptake (principal considerations are phenylephrine and pseudoephedrine containing compounds which need to be discontinued for 48 hours, and labetalol which needs to be discontinued for 6 weeks)